… phase 1/2 study of CBU-derived engineered NK cells expressing an anti-CD19 CAR, a cytokine
(IL-15) and the iC9 safety switch … patients with relapsed or refractory B cell malignancies. …

… Bhoj et al. reported a clinical trial about CD19-CAR T persistence … allogeneic anti-CD19 CAR
T cells could effectively treat B-… to ensure the safety of genetically modified cells by selective …

… Furthermore, allogeneic NK cells have a proven track record of safety after infusion for … a
phase 1 and 2 trial to assess the safety and efficacy of escalating doses of CAR-NK cells for the …

… T cells and results from a previous clinical trial that tested T … confounding factors that arise
in comparing different trials were … had never received an allogeneic-stem-cell transplant and …

… , safety of bispecific CAR T cells and clinical activity in both B-… Two patients received a
consolidative allogeneic stem cell … monospecific CAR is dependent on numerous factors, …

… -501A, alternative allogeneic anti-CD19 CAR-T products … increase in clinical trials using
CAR-NK cells and investigating … infusion of CAR-NK cells (10 7 CAR-NK cells per kilogram of …

… Here, we report the effectiveness and safety of our clinical … /RB cell NHL and evaluated the
risk factors affecting response … UCAR-T19, an allogeneic product containing an RQR8 domain …

… the first report of a Phase I clinical trial using healthy donor-… using CAR-T cells targeting
CD19, patients with r/r B cell … host T and NK cells would still become major hurdles against the …

… Allogeneic stem cell transplantation reduces relapse rates in … TRASFORM phase III trial
evaluated the efficacy and safety … T cells, other innate effector cells, such as natural killer cells (…

… The starting UCART19 cell dose of 6 × 10 6 cells (equivalent to 1 × 10 5 cells per kg for 60
… dose of 1 × 10 6 CAR T cells per kg shown to be safe and efficacious for other autologous …